| SVATON, Martin, Milada ZEMANOVA, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, Vitezslav KOLEK, Juraj KULTAN, Leona KOUBKOVA, Alzbeta BEJCKOVA, Frantisek SALAJKA, Michal HRNCIARIK, Bohuslav MELICHAR, David VRANA, Marek KONECNY, Renata CHLOUPKOVÁ a Milos PESEK. Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. Anticancer Research. Athens: International Institute of Anticancer Research, 2018, roč. 38, č. 12, s. 6771-6782. ISSN 0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.13048. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1489189,
author = {Svaton, Martin and Zemanova, Milada and Skřičková, Jana and Jakubíková, Lenka and Kolek, Vitezslav and Kultan, Juraj and Koubkova, Leona and Bejckova, Alzbeta and Salajka, Frantisek and Hrnciarik, Michal and Melichar, Bohuslav and Vrana, David and Konecny, Marek and Chloupková, Renata and Pesek, Milos},
article_location = {Athens},
article_number = {12},
doi = {http://dx.doi.org/10.21873/anticanres.13048},
keywords = {Nivolumab; non-small cell lung cancer; overall survival; progression-free survival; biomarker},
language = {eng},
issn = {0250-7005},
journal = {Anticancer Research},
title = {Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer},
volume = {38},
year = {2018}
}
TY - JOUR
ID - 1489189
AU - Svaton, Martin - Zemanova, Milada - Skřičková, Jana - Jakubíková, Lenka - Kolek, Vitezslav - Kultan, Juraj - Koubkova, Leona - Bejckova, Alzbeta - Salajka, Frantisek - Hrnciarik, Michal - Melichar, Bohuslav - Vrana, David - Konecny, Marek - Chloupková, Renata - Pesek, Milos
PY - 2018
TI - Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer
JF - Anticancer Research
VL - 38
IS - 12
SP - 6771-6782
EP - 6771-6782
PB - International Institute of Anticancer Research
SN - 02507005
KW - Nivolumab
KW - non-small cell lung cancer
KW - overall survival
KW - progression-free survival
KW - biomarker
N2 - Aim: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan Meier method and Cox analysis. Results: Among clinical parameters, histology was significantly associated with progression free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. Conclusion: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment. Among the laboratory parameters, our analysis identified a laboratory panel reflecting chronic inflammation as a potential predictive marker of nivolumab treatment.
ER -
SVATON, Martin, Milada ZEMANOVA, Jana SKŘIČKOVÁ, Lenka JAKUBÍKOVÁ, Vitezslav KOLEK, Juraj KULTAN, Leona KOUBKOVA, Alzbeta BEJCKOVA, Frantisek SALAJKA, Michal HRNCIARIK, Bohuslav MELICHAR, David VRANA, Marek KONECNY, Renata CHLOUPKOVÁ a Milos PESEK. Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2018, roč.~38, č.~12, s.~6771-6782. ISSN~0250-7005. Dostupné z: https://dx.doi.org/10.21873/anticanres.13048.
|
